Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

The lack of validated immunological correlates of protection makes tuberculosis vaccine development difficult and expensive. Using intradermal bacille Calmette-Guréin (BCG) as a surrogate for aerosol Mycobacterium tuberculosis (M.tb) in a controlled human infection model could facilitate vaccine dev...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Harris, S, White, A, Stockdale, L, Tanner, R, Sibley, L, Sarfas, C, Meyer, J, Peter, J, O'Shea, M, Manjaly Thomas, Z, Hamidi, A, Satti, I, Dennis, M, McShane, H, Sharpe, S
Formato:	Journal article
Publicado em:	Elsevier 2017

Registos relacionados

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
Por: Tanner, R, et al.
Publicado em: (2021)

Optimisation of a human BCG challenge model
Por: Wilkie, M, et al.
Publicado em: (2015)

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Por: Peralta-Álvarez, MP, et al.
Publicado em: (2024)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
Por: Harris, S, et al.
Publicado em: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
Por: Harris, SA, et al.
Publicado em: (2014)

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Por: Marco Polo Peralta-Álvarez, et al.
Publicado em: (2024-11-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
Por: Tanner, R, et al.
Publicado em: (2021)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
Por: Rachel Tanner, et al.
Publicado em: (2021-01-01)

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
Por: Alvarez, MPP, et al.
Publicado em: (2024)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Por: Minhinnick, A, et al.
Publicado em: (2016)

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
Por: Marco Polo Peralta Alvarez, et al.
Publicado em: (2024-05-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 1; peer review: 2 approved]
Por: Rachel Tanner, et al.
Publicado em: (2021-03-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 2; peer review: 2 approved]
Por: Rachel Tanner, et al.
Publicado em: (2021-09-01)

Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model
Por: Matsumiya, M, et al.
Publicado em: (2014)

Immune cell population dynamics following neonatal BCG vaccination and aerosol BCG revaccination in rhesus macaques
Por: Laura Sibley, et al.
Publicado em: (2024-07-01)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
Por: Sheehan, S, et al.
Publicado em: (2015)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Por: Satti, I, et al.
Publicado em: (2014)

Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
Por: Andrew D. White, et al.
Publicado em: (2023-10-01)

Development of a primate model for tuberculosis vaccine research: IFN-gamma responses induced by BCG vaccination and M-tuberculosis infection in macaques
Por: Dowall, S, et al.
Publicado em: (2007)

Induction of functional specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
Por: Bitencourt, J, et al.
Publicado em: (2021)

IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against <i>M. tb</i> Challenge
Por: Alexandra L. Morrison, et al.
Publicado em: (2023-10-01)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
Por: Fletcher, H, et al.
Publicado em: (2016)

Predicting IFN-γ responses after BCG vaccination in humans from macaques: A proof-of-concept study of Immunostimulation/Immunodynamic modelling methods
Por: Rhodes, S, et al.
Publicado em: (2017)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Por: Harris, S, et al.
Publicado em: (2011)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.
Por: Fletcher, H, et al.
Publicado em: (2016)

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.
Por: Fletcher, H, et al.
Publicado em: (2013)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
Por: Villarreal-Ramos, B, et al.
Publicado em: (2017)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
Por: Harris, SA, et al.
Publicado em: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
Por: Satti, I, et al.
Publicado em: (2014)

Characterization of the Infant Immune System and the Influence and Immunogenicity of BCG Vaccination in Infant and Adult Rhesus Macaques
Por: Charlotte Sarfas, et al.
Publicado em: (2021-10-01)

The humoral immune response to BCG vaccination
Por: Tanner, R, et al.
Publicado em: (2019)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
Por: O'Shea, M, et al.
Publicado em: (2018)

Revaccination with BCG: does it work?
Por: McShane, H
Publicado em: (2024)

Understanding BCG is the key to improving it.
Por: McShane, H
Publicado em: (2013)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
Por: Julia Bitencourt, et al.
Publicado em: (2022-01-01)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
Por: Helen A. Fletcher, et al.
Publicado em: (2016-04-01)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Por: Satti, I, et al.
Publicado em: (2022)

Optimization of a human bacille Calmette-Guerin challenge model: a tool to evaluate antimycobacterial immunity
Por: Minhinnick, A, et al.
Publicado em: (2015)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Por: Minassian, A, et al.
Publicado em: (2011)

TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination
Por: Andrew D. White, et al.
Publicado em: (2021-08-01)